Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Potentiation of in vitro and in vivoantitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells

Figure 2

The effect of P276-00, doxorubicin and the combination of doxorubicin followed by P276-00 on cell proliferation, cell cycle and on recovery of cells after the treatment. (A) Cells were treated with 200 nM doxorubicin for 24 h or 800 nM of P276-00 for 72 h or combination of both. (B) Cells were treated with 100 nM doxorubicin for 24 h or 1200 nM P276-00 for 96 h or combination of both. (C) Percent of cell population in different phases of cell cycle. (D) Percent of cell population in sub-G1 phase after treatment with either drug alone or combination for 96 h and 120 h and (E) Recovery of cells after the drug treatment was studied at different timepoints i.e. 0 h, 6 h, 18 h, 24 h and 48 h. Cell cycle analysis using Flow cytometry shows the percentage apoptosis in drug alone and combination treatment in comparison to untreated control.

Back to article page